Celcuity (NASDAQ:CELC) Director Sells $330,810.00 in Stock

Celcuity, Inc. (NASDAQ:CELC) Director Richard Buller sold 3,000 shares of the business’s stock in a transaction on Tuesday, March 31st. The shares were sold at an average price of $110.27, for a total value of $330,810.00. Following the completion of the sale, the director directly owned 6,760 shares in the company, valued at approximately $745,425.20. This represents a 30.74% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Celcuity Stock Performance

Shares of NASDAQ:CELC opened at $112.63 on Friday. The company has a debt-to-equity ratio of 3.20, a current ratio of 10.55 and a quick ratio of 10.55. The business’s fifty day moving average price is $109.90 and its two-hundred day moving average price is $92.94. Celcuity, Inc. has a fifty-two week low of $7.57 and a fifty-two week high of $120.32. The stock has a market capitalization of $5.44 billion, a price-to-earnings ratio of -29.72 and a beta of 0.41.

Celcuity (NASDAQ:CELC) last issued its quarterly earnings data on Wednesday, March 25th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.09. As a group, analysts predict that Celcuity, Inc. will post -2.62 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Hsbc Holdings PLC bought a new stake in Celcuity during the 4th quarter worth about $1,058,000. Seven Fleet Capital Management LP bought a new position in shares of Celcuity in the fourth quarter worth about $783,000. Invesco Ltd. lifted its position in shares of Celcuity by 4.9% during the fourth quarter. Invesco Ltd. now owns 147,938 shares of the company’s stock worth $14,755,000 after purchasing an additional 6,928 shares in the last quarter. Mercer Global Advisors Inc. ADV acquired a new position in shares of Celcuity during the fourth quarter worth approximately $376,000. Finally, KVP Capital Advisors LP bought a new stake in shares of Celcuity during the fourth quarter valued at approximately $399,000. Institutional investors and hedge funds own 63.33% of the company’s stock.

Wall Street Analysts Forecast Growth

CELC has been the topic of a number of recent analyst reports. Wolfe Research restated an “outperform” rating and issued a $110.00 price target on shares of Celcuity in a research report on Thursday, March 12th. Wells Fargo & Company assumed coverage on shares of Celcuity in a report on Friday, December 12th. They set an “overweight” rating and a $126.00 price objective for the company. Wall Street Zen upgraded shares of Celcuity from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Celcuity in a report on Wednesday, January 21st. Finally, Needham & Company LLC restated a “buy” rating and set a $122.00 price target on shares of Celcuity in a research report on Thursday, March 26th. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $109.88.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.